
Sign up to save your podcasts
Or
Drs John M. Kane and Mitchell Arnovitz discuss assessment of patients for negative symptoms of schizophrenia and the potential of MDMA in alleviating these symptoms in supervised treatment settings.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984490). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Schizophrenia https://emedicine.medscape.com/article/288259-overview
MDMA for the Treatment of Negative Symptoms in Schizophrenia https://pubmed.ncbi.nlm.nih.gov/35743326/
MDMA (Ecstasy/Molly) https://nida.nih.gov/publications/drugfacts/mdma-ecstasymolly
The NIMH-MATRICS Consensus Statement on Negative Symptoms https://pubmed.ncbi.nlm.nih.gov/16481659/
The Current Conceptualization of Negative Symptoms in Schizophrenia https://pubmed.ncbi.nlm.nih.gov/28127915/
Akinesia https://www.ncbi.nlm.nih.gov/books/NBK562177/
An Assessment of Five (PANSS, SAPS, SANS, NSA-16, CGI-SCH) Commonly Used Symptoms Rating Scales in Schizophrenia and Comparison to Newer Scales (CAINS, BNSS) https://pubmed.ncbi.nlm.nih.gov/29430333/
Ecological Momentary Assessment https://pubmed.ncbi.nlm.nih.gov/18509902/
Schizophrenia Medication https://emedicine.medscape.com/article/288259-medication#2
Cariprazine, a Broad-Spectrum Antipsychotic for the Treatment of Schizophrenia: Pharmacology, Efficacy, and Safety https://pubmed.ncbi.nlm.nih.gov/34091867/
DRD3 Dopamine Receptor D3 [Homo sapiens (human)] https://www.ncbi.nlm.nih.gov/gene/1814
MDA https://dictionary.apa.org/mda
Transcranial Magnetic Stimulation: A Review of Its Evolution and Current Applications https://pubmed.ncbi.nlm.nih.gov/31359968/
Memantine https://www.ncbi.nlm.nih.gov/books/NBK500025/
Making MDMA a Medicine (II) (Re)scheduling for Schedule I Substances https://maps.org/news/bulletin/making-mdma-a-medicine-ii-rescheduling-for-schedule-1-substances/
Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors https://www.ncbi.nlm.nih.gov/books/NBK548187/
Metaplasticity: Tuning Synapses and Networks for Plasticity https://pubmed.ncbi.nlm.nih.gov/18401345/
MDMA-Assisted Psychotherapy for Treatment of Posttraumatic Stress Disorder: A Systematic Review With Meta-Analysis https://pubmed.ncbi.nlm.nih.gov/34708874/
Reduction in Social Anxiety After MDMA-Assisted Psychotherapy With Autistic Adults: A Randomized, Double-Blind, Placebo-Controlled Pilot Study https://pubmed.ncbi.nlm.nih.gov/30196397/
Prefrontal Cortex-Nucleus Accumbens Interaction: In Vivo Modulation by Dopamine and Glutamate in the Prefrontal Cortex https://pubmed.ncbi.nlm.nih.gov/18508116/
Serotonin Syndrome https://emedicine.medscape.com/article/2500075-overview
4.9
77 ratings
Drs John M. Kane and Mitchell Arnovitz discuss assessment of patients for negative symptoms of schizophrenia and the potential of MDMA in alleviating these symptoms in supervised treatment settings.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984490). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Schizophrenia https://emedicine.medscape.com/article/288259-overview
MDMA for the Treatment of Negative Symptoms in Schizophrenia https://pubmed.ncbi.nlm.nih.gov/35743326/
MDMA (Ecstasy/Molly) https://nida.nih.gov/publications/drugfacts/mdma-ecstasymolly
The NIMH-MATRICS Consensus Statement on Negative Symptoms https://pubmed.ncbi.nlm.nih.gov/16481659/
The Current Conceptualization of Negative Symptoms in Schizophrenia https://pubmed.ncbi.nlm.nih.gov/28127915/
Akinesia https://www.ncbi.nlm.nih.gov/books/NBK562177/
An Assessment of Five (PANSS, SAPS, SANS, NSA-16, CGI-SCH) Commonly Used Symptoms Rating Scales in Schizophrenia and Comparison to Newer Scales (CAINS, BNSS) https://pubmed.ncbi.nlm.nih.gov/29430333/
Ecological Momentary Assessment https://pubmed.ncbi.nlm.nih.gov/18509902/
Schizophrenia Medication https://emedicine.medscape.com/article/288259-medication#2
Cariprazine, a Broad-Spectrum Antipsychotic for the Treatment of Schizophrenia: Pharmacology, Efficacy, and Safety https://pubmed.ncbi.nlm.nih.gov/34091867/
DRD3 Dopamine Receptor D3 [Homo sapiens (human)] https://www.ncbi.nlm.nih.gov/gene/1814
MDA https://dictionary.apa.org/mda
Transcranial Magnetic Stimulation: A Review of Its Evolution and Current Applications https://pubmed.ncbi.nlm.nih.gov/31359968/
Memantine https://www.ncbi.nlm.nih.gov/books/NBK500025/
Making MDMA a Medicine (II) (Re)scheduling for Schedule I Substances https://maps.org/news/bulletin/making-mdma-a-medicine-ii-rescheduling-for-schedule-1-substances/
Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors https://www.ncbi.nlm.nih.gov/books/NBK548187/
Metaplasticity: Tuning Synapses and Networks for Plasticity https://pubmed.ncbi.nlm.nih.gov/18401345/
MDMA-Assisted Psychotherapy for Treatment of Posttraumatic Stress Disorder: A Systematic Review With Meta-Analysis https://pubmed.ncbi.nlm.nih.gov/34708874/
Reduction in Social Anxiety After MDMA-Assisted Psychotherapy With Autistic Adults: A Randomized, Double-Blind, Placebo-Controlled Pilot Study https://pubmed.ncbi.nlm.nih.gov/30196397/
Prefrontal Cortex-Nucleus Accumbens Interaction: In Vivo Modulation by Dopamine and Glutamate in the Prefrontal Cortex https://pubmed.ncbi.nlm.nih.gov/18508116/
Serotonin Syndrome https://emedicine.medscape.com/article/2500075-overview
77,846 Listeners
43,483 Listeners
111,917 Listeners
56,285 Listeners
27,238 Listeners
190 Listeners
563 Listeners
47,886 Listeners
465 Listeners
38,676 Listeners
691 Listeners
113 Listeners
391 Listeners
112 Listeners
2,300 Listeners